特异性靶向5-羟色胺2B受体(5-HT2BR)在硬皮病皮肤小鼠模型及离体模型中的抗纤维化作用
本研究评估高选择性5-HT2BR抑制剂AM1476在三种小鼠SSc模型及SSc患者离体皮肤切片中的抗纤维化效果。AM1476在耐受剂量下减少羟脯氨酸累积和皮肤/肺纤维化重塑,疗效与尼达尼布相当,并降低SSc皮肤切片中SSc特异性标志基因表达,对成纤维细胞活化相关基因的调控比霉酚酸酯更明显。
要点
- AM1476在三种小鼠SSc模型中减少皮肤和/或肺的羟脯氨酸累积及纤维化重塑,疗效与尼达尼布相当。
- 在SSc患者离体皮肤切片中,AM1476降低SSc特异性标志基因表达,对成纤维细胞活化相关基因调控比霉酚酸酯更明显。
- AM1476在1期试验中耐受性良好,进一步临床试验正在计划中。
核心结论
- AM1476是一种高选择性5-HT2BR抑制剂,在三种小鼠SSc模型中改善纤维化,并直接在SSc皮肤中使纤维化相关基因表达正常化。
- 由于AM1476在1期试验中也表现出良好耐受性,目前正在计划进一步的临床试验。
研究设计与样本
- 在博来霉素诱导肺纤维化小鼠、Tsk-1小鼠和硬皮病样慢性移植物抗宿主病小鼠三种模型中评估AM1476的抗纤维化效果。
- 在SSc患者的精密切割皮肤切片中进一步验证AM1476的抗纤维化效果。
主要发现
- 体外实验中,AM1476对5-HT2BR的选择性高于包括其他5-HT受体在内的200多种其他受体。
- 在三种小鼠模型中,AM1476在耐受良好的剂量下减少皮肤和/或肺的羟脯氨酸累积及纤维化组织重塑,疗效与尼达尼布相当。
- 在SSc皮肤精密切割皮肤切片中,AM1476治疗降低SSc特异性标志基因的表达。
- 与霉酚酸酯相比,AM1476对成纤维细胞活化和纤维化重塑相关术语的调控更明显。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic sclerosis (SSc) is a connective tissue disease with fibrotic remodeling of the skin and various internal organs. SSc is associated with the highest case-specific mortality of all rheumatic autoimmune diseases with limited antifibrotic treatment options. Here, we evaluated the therapeutic effects of the highly selective 5-hydroxytryptamine 2B receptor (5-HT2BR) inhibitor AM1476. METHODS: The antifibrotic effects of AM1476 were evaluated in the mouse models of bleomycin-induced pulmonary fibrosis in Tsk-1 mice and in mice with sclerodermatous chronic graft-versus-host disease. For further validation, the antifibrotic effects of AM1476 were analyzed in precision cut skin (PCS) slices from patients with SSc. RESULTS: AM1476 demonstrated high selectivity for 5-HT2BR over more than 200 other receptors, including other 5-HT receptors in vitro. AM1476 reduced accumulation of hydroxyproline and fibrotic tissue remodeling of skin and/or lungs in all three mouse models at well-tolerated doses with a comparable efficacy to that of nintedanib. In PCS of SSc skin, treatment with AM1476 reduced the expression of SSc-specific signature genes. AM1476 demonstrated more pronounced regulation of terms related to fibroblast activation and fibrotic remodeling than mycophenolate mofetil. CONCLUSION: We describe AM1476 as a highly selective inhibitor of 5-HT2BR. Treatment with AM1476 ameliorated fibrosis in three mouse models of SSc and normalized the expression of fibrosis-related genes directly in SSc skin. Because AM1476 also demonstrated good tolerability in a phase 1 trial, further clinical trials with AM1476 are currently in the planning stage.
引用
- Trinh-Minh T, Tran-Manh C, Györfi AH, et al. Antifibrotic effects of specific targeting of the 5-hydroxytryptamine 2B receptor (5-HT2BR) in murine models and ex vivo models of scleroderma skin. Arthritis Rheumatol. 2025. PMID: 40064593. doi:10.1002/art.43151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。